An interim analysis of the small, single-arm ANNEXA-4 study of Portola Pharmaceuticals Inc.'sAndexXa antidote for Factor Xa anticoagulants raised questions about an 18% rate of thrombotic events, but the company explains that this is in line with what would be expected for an at-risk, elderly patient population.
Portola Defends AndexXa Antidote Safety, Says Thrombotic Events In Line
Interim analysis of ANNEXA-4 study published in NEJM supports case for AndexXa approval, but 18% thrombosis rate raised some eyebrows.
More from Approvals
More from Product Reviews
• By
Sponsors of three drugs that are in the final stages of the EU regulatory review cycle are due to make the case for marketing approval before the European Medicines Agency.
• By
The European Medicines Agency is this week set to issue an opinion on whether pan-EU marketing should be granted to Lilly’s Alzheimer’s disease drug donanemab.
• By
The European Medicines Agency is re-evaluating the marketing application for Aplidin. The initial application was rejected in 2018, but that rejection was revoked last year following a court case for another company’s drug that clarified impartiality requirements for experts consulted by the EMA.